Insider · CIK 0001420822
Dennis M Lanfear
ceopresidentofficerdirector
Files at CHRS (Coherus Oncology, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 23, 2026 | CHRS Coherus Oncology, Inc. | AGrant or award Common Stock | +375,000 | $0.00 | $0 | 1,048,235 | Jan 26, 2026 |
| Jan 23, 2026 | CHRS Coherus Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Jan 26, 2026 |
| Jan 20, 2026 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -11,839 | $1.55 | $18k | 673,235 | Jan 22, 2026 |
| May 7, 2025 | CHRS Coherus Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +375,000 | $0.00 | $0 | 375,000 | May 9, 2025 |
| Jan 20, 2025 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -11,810 | $1.39 | $16k | 685,074 | Jan 22, 2025 |
| Jan 10, 2025 | CHRS Coherus Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +575,000 | $0.00 | $0 | 575,000 | Jan 14, 2025 |
| Jan 4, 2025 | CHRS Coherus Oncology, Inc. | FTax withholding Common Stock | -11,810 | $1.66 | $20k | 696,884 | Jan 7, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.